Background: The Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia. Methods: We retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5. Results: 262 patients were enrolled with a follow-up period of 11 months (IQR 5-15). No early or late serious adverse events (Clavien III-IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively. Conclusions: In our series, water vapor intraprostatic injections seem to be an effective and safe procedure.
Composite urinary and sexual outcomes after Rezum. an analysis of predictive factors from an Italian multi-centric study / Campobasso, Davide; Siena, Giampaolo; Chiodini, Paolo; Conti, Enrico; Franzoso, Francesco; Maruzzi, Daniele; Martinelli, Evangelista; Varvello, Francesco; De Nunzio, Cosimo; Autorino, Riccardo; Somani, Bhaskar Kumar; Ferrari, Giovanni; Cindolo, Luca. - In: PROSTATE CANCER AND PROSTATIC DISEASES. - ISSN 1365-7852. - Aug 30(2022), pp. 1-5. [10.1038/s41391-022-00587-6]
Composite urinary and sexual outcomes after Rezum. an analysis of predictive factors from an Italian multi-centric study
De Nunzio, Cosimo;Ferrari, Giovanni;
2022
Abstract
Background: The Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia. Methods: We retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5. Results: 262 patients were enrolled with a follow-up period of 11 months (IQR 5-15). No early or late serious adverse events (Clavien III-IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively. Conclusions: In our series, water vapor intraprostatic injections seem to be an effective and safe procedure.File | Dimensione | Formato | |
---|---|---|---|
Campobasso_Composite-urinary-and sexual_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
473.13 kB
Formato
Adobe PDF
|
473.13 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.